%0 Journal Article
%T KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment
%A Cummings, Amy Lauren
%A Santoso, Kate M.
%A Goldman, Jonathan W.
%J Translational Lung Cancer Research
%D 2019
%B 2019
%9 
%! KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment
%K 
%X With 15 new non-small cell lung cancer (NSCLC) United States Food & Drug Association (FDA) approvals in the past 5 years, the alignment of academia, pharmaceutical companies, and government regulatory agencies to develop better cancer therapies and quickly make them available to patients has led to a rapidly evolving standard-of-care (1).  While undoubtedly beneficial to NSCLC patients, one ramification is that the environment in which a clinical trial is designed may not be same one in which its results are reported. Such is the case with KEYNOTE-021 Cohorts D and H (KN-021 D/H) (2).
%U https://tlcr.amegroups.org/article/view/31206
%V 8
%N 5
%P 706-709
%@ 2226-4477